🇺🇸 OMARIGLIPTIN in United States

20 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Autoimmune Disorder — 2 reports (10%)
  2. Diabetes Mellitus — 2 reports (10%)
  3. Diarrhoea — 2 reports (10%)
  4. Fall — 2 reports (10%)
  5. Glycosylated Haemoglobin Increased — 2 reports (10%)
  6. Iron Deficiency Anaemia — 2 reports (10%)
  7. Low Density Lipoprotein Increased — 2 reports (10%)
  8. Malaise — 2 reports (10%)
  9. Mycobacterial Infection — 2 reports (10%)
  10. Mycobacterium Avium Complex Infection — 2 reports (10%)

Source database →

OMARIGLIPTIN in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is OMARIGLIPTIN approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for OMARIGLIPTIN in United States?

Marketing authorisation holder not available in our data.